Obesity as a risk factor for antipsychotic noncompliance

Schizophrenia Research

Volumn 66, Issue 1, 2004, Pages 51-57

  Weiden, Peter J ^a   Mackell, Joan A ^b   McDonnell, Diana D ^c  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

^c Consumer Health Sciences ^*  (United States)

Author keywords

Antipsychotic; Obesity; Weight problem

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; ASSOCIATION; BODY HEIGHT; BODY MASS; BODY WEIGHT; DEMOGRAPHY; HUMAN; MENTAL STRESS; OBESITY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SELF REPORT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0347596648     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(02)00498-X     Document Type: Article

References (26)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. 156:1999;1686-1696.
2. Babiker I.E. Noncompliance in schizophrenia. Psychiatr. Dev. 4:1986;329-337.
3. Becker M.H. The health belief model and personal health behaviors. Health Educ. Monogr. 2:1974;324-473.
4. Berken G.H., Weinstein D.O., Stern W.C. Weight gain. A side-effect of tricyclic antidepressants. J. Affect. Disord. 7:1984;133-138.
5. Cookson J.C. Side effects during long-term treatment with depot antipsychotic medication. Clin. Neuropharmacol. 14(Suppl. 2):1991;S24-S330.
6. Cramer J.A., Mattson R.H., Prevey M.L., Scheyer R.D., Ouellette V.L. How often is medication taken as prescribed? A novel assessment technique. JAMA. 261:1989;3273-3277.
7. Devlin M.J., Yanovski S.Z., Wilson G.T. Obesity: what mental health professionals need to know. Am. J. Psychiatry. 157:2000;854-866.
8. Dupuy, H., 1984. The Psychological General Well-Being (PGWB) Index. In: Wenger, N., Mattson, M., Furberg, C., Elinson, J. (Eds.), Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Le Jacq Publishing, Greenwich, CT, pp. 170-183, 353-356.
9. Fleischhacker W.W., Meise U., Gunther V., Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr. Scand., Suppl. 382:1994;11-15.
10. Hogan T.P., Awad A.G. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol. Med. 22:1992;347-352.
11. Hogan T.P., Awad A.G., Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol. Med. 13:1983;177-183.
12. Janz N.K., Becker M.H. The Health Belief Model: a decade later. Health Educ. Q. 11:1984;1-47.
13. Kapur S., Ganguli R., Ulrich R., Raghu U. Use of random-sequence riboflavin as a marker of medication compliance in chronic schizophrenics. Schizophr. Res. 6:1991;49-53.
14. Meyers A.W., Klesges R.C., Winders S.E., Ward K.D., Peterson B.A., Eck L.H. Are weight concerns predictive of smoking cessation? A prospective analysis. J. Consult. Clin. Psychol. 65:1997;448-452.
15. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obes. Res. 6(Suppl. 2):1998;51S-209S.
16. Polonsky W.H., Anderson B.J., Lohrer P.A., Aponte J.E., Jacobson A.M., Cole C.F. Insulin omission in women with IDDM. Diabetes Care. 17:1994;1178-1185.
17. Revicki D.A., Leidy N.K., Howland L. Evaluating the psychometric characteristics of the Psychological General Well-Being Index with a new response scale. Qual. Life Res. 5:1996;419-425.
18. Rosenberg M.J., Waugh M.S., Meehan T.E. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception. 51:1995;283-288.
19. SPSS for Windows. Release 9.0.0. 1998;SPSS, Chicago.
20. Van Putten T., May P.R. Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Arch. Gen. Psychiatry. 35:1978;477-480.
21. Van Putten T., May P.R., Marder S.R. Subjective responses to thiothixene and chlorpromazine. Psychopharmacol. Bull. 16:1980;36-38.
22. Van Putten T., May P.R., Marder S.R., Wittmann L.A. Subjective response to antipsychotic drugs. Arch. Gen. Psychiatry. 38:1981;187-190.
23. Weiden, P.J., Mackell, J., 1999. Differing side effect burden with newer antipsychotics. Presented at: 39th Annual New Clinical Drug Evaluation Unit (NCDEU) Conference, Boca Raton, FL, Poster No. 87.
24. Weiden P.J., Mott T. Recognition and management of neuroleptic noncompliance in schizophrenia. Shriqui C.L., Nasrallah H.A. Contemporary Issues in the Treatment of Schizophrenia. 1995;411-434 American Psychiatric Press, Washington, DC.
25. Weiden P.J., Olfson M. Cost of relapse in schizophrenia. Schizophr. Bull. 21:1995;419-429.
26. Weiden P., Rapkin B., Mott T., Zygmunt A., Goldman D., Horvitz Lennon M., Frances A. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr. Bull. 20:1994;297-310.